Australian clinical research organization Nucleus Network announced Tuesday the commencement of dosing the first human participants for the Phase 1 trial of a COVID-19 vaccine on behalf of US -based biotechnology company Novavax.
KAZINFORM Thai COVID-19 vaccine research team on Monday said it will be recruiting human beings for vaccine trials later this year following an ongoing three months test on monkeys.
There are now more than 100 COVID-19 vaccine candidates in development globally, Ad5-nCoV is the first to be evaluated in humans.
"These results provide strong evidence that the vaccine candidate will be highly immunogenic in humans, leading to protection from COVID-19 and thus helping to control the spread of this disease", the assertion mentioned.
To get there, top vaccine makers have agreed to share data and lend the use of their clinical trial networks to competitors in the event their own candidate fails, the scientists said.
The most common adverse reactions were mild pain at the injection site reported in over half (54%, 58/108) of vaccine recipients, fever (46%, 50/108), fatigue (44%, 47/108), headache (39%, 42/108), and muscle pain (17%, 18/108).
A study published last Friday in the Lancet says the formulation from China's CanSino Biologics Inc. needs more trials to determine whether it can actually protect against SARS-CoV-2, the virus that causes COVID-19.
Within two weeks of vaccination, all dose levels of the vaccine triggered some level of immune response in the form of binding antibodies (that can bind to the coronavirus but do not necessarily attack it - low-dose group 16/36, 44%; medium dose 18/36, 50%; high dose 22/36, 61%), and some participants had detectable neutralizing antibodies against SARS-CoV-2 (low-dose group 10/36, 28%; medium dose 11/36, 31%; high dose 15/36, 42%). Novavax said it identified NVX-CoV2373 as its lead SARS-CoV-2 candidate following pre-clinical testing that demonstrated high immunogenicity and high levels of neutralising antibodies. So, we're trying to block that process. "We look forward to sharing the clinical results in July and, if promising, quickly initiating the Phase II portion of the trial". For the first time, this will include participants over 60 years old, an important target population for the vaccine. Also Read:China's "Batwoman": Coronavirus 'Just Tip of the Iceberg, ' More Pandemics May Arrive "Administering our vaccine in the first participants of this clinical trial is a significant achievement, bringing us one step closer toward addressing the fundamental need for a vaccine in the fight against the global Covid-19 pandemic", said Stanley C. Erck, the president, and CEO of Novavax.
Silent Hill returns in new Dead By Daylight DLC
Beahviour says it's open to any collaboration, regardless of the medium as long as it fits with the Dead by Daylight world. After a call, Cote said both parties realised this collaboration was the "perfect" crossover.